Irinotecan is inactive as a first-line treatment, but plays an important part in gastric cancer treatment Hiroya Takiuchi Editorial 01 March 2011 Pages: 1 - 3
Why is the coexistence of gastric cancer and duodenal ulcer rare? Examination of factors related to both gastric cancer and duodenal ulcer Hideyuki UbukataHiroyuki NagataTakafumi Tabuchi Review Article 20 January 2011 Pages: 4 - 12
Japanese Gastric Cancer Association Task Force for Research Promotion: clinical utility of 18F-fluoro-2-deoxyglucose positron emission tomography in gastric cancer. A systematic review of the literature Hideaki ShimadaShinichi OkazumiKoji Murakami Review Article 18 February 2011 Pages: 13 - 21
Correlation between endoscopic macroscopic type and invasion depth for early esophagogastric junction adenocarcinomas Ichiro OdaSeiichiro AbeTakuji Gotoda Original Article 28 January 2011 Pages: 22 - 27
Management of adjuvant S-1 therapy after curative resection of gastric cancer: dose reduction and treatment schedule modification Satoru IwasaYasuhide YamadaYasuhiro Shimada Original Article 16 February 2011 Pages: 28 - 34
Depth-predicting score for differentiated early gastric cancer Seiichiro AbeIchiro OdaTakuji Gotoda Original Article 17 February 2011 Pages: 35 - 40
Increased Slug and decreased E-cadherin expression is related to poor prognosis in patients with gastric cancer Yasuto UchikadoHiroshi OkumuraShoji Natsugoe Original Article 28 January 2011 Pages: 41 - 49
Effectiveness and safety of oxaliplatin compared to cisplatin for advanced, unresectable gastric cancer: a systematic review and meta-analysis Francesco MontagnaniGina TurrisiGiammaria Fiorentini Original Article 23 February 2011 Pages: 50 - 55
Clinical impact of a strategy involving endoscopic submucosal dissection for early gastric cancer: determining the optimal pathway Satoru NonakaIchiro OdaTakuji Gotoda Original Article 17 February 2011 Pages: 56 - 62
Adjuvant chemoradiation for resected gastric cancer: a 10-year experience Amy T. Y. ChangWai Tong NgAnne W. M. Lee Original Article 17 February 2011 Pages: 63 - 71
Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002) Hiroyuki NaraharaHiroyasu IishiYuh Sakata Original Article Open access 23 February 2011 Pages: 72 - 80
Assessing clinical benefit response in the treatment of gastric malignant ascites with non-measurable lesions: a multicenter phase II trial of paclitaxel for malignant ascites secondary to advanced/recurrent gastric cancer Haruhiko ImamotoKoji ObaHitoshi Shiozaki Original Article 17 February 2011 Pages: 81 - 90
Trans-vaginal specimen extraction following totally laparoscopic subtotal gastrectomy in early gastric cancer Sang-Ho JeongYoung-Joon LeeWoo-Song Ha Technical Note 25 January 2011 Pages: 91 - 96